Antithrombin Iii Human
drugOn this page
Also known as AntithrombinAntithrombin iiiAntithrombin iii (human)humanAntithrombine iiiAntitrombina iiiAt-iiiAtenativAtnativHeparin cofactor bKyberninKybernin pORG 10849Thrombate iii
Summary
Antithrombin Iii Human (CHEMBL2108574) is a phase-3 clinical-stage unknown (ATC B01AB02); indicated across 7 conditions including thrombotic disease and hereditary antithrombin deficiency.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- ATC class: B01AB02
- Indications: 7 conditions
- Clinical trials: 19
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108574 |
| Name | Antithrombin Iii Human |
| Type | Unknown |
| Max phase | 3 |
| ATC | B01AB02 |
Also known as: Antithrombin, Antithrombin iii, Antithrombin iii (human), Antithrombin iii human, human, Antithrombine iii, Antitrombina iii, At-iii, Atenativ, Atnativ, Heparin cofactor b, Kybernin
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
7 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| thrombotic disease | 4 | MONDO:0000831 | HP:0004419 |
| hereditary antithrombin deficiency | 3 | MONDO:0013144 | HP:0001976 |
| disseminated intravascular coagulation | 3 | MONDO:0001243 | HP:0005521 |
| hemophilia A | 3 | MONDO:0010602 | MONDO:0010602 |
| congenital heart disease | 1 | MONDO:0005453 | EFO:0005207 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 19.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 5 |
| PHASE2 | 4 |
| PHASE4 | 3 |
| PHASE3 | 3 |
| PHASE1 | 3 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01201070 | PHASE4 | UNKNOWN | Study of Administration Of Antithrombin in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery |
| NCT01913444 | PHASE4 | WITHDRAWN | Pharmacokinetic Study of Recombinant AT III in Neonates Undergoing ECMO |
| NCT02278575 | PHASE4 | WITHDRAWN | Atenativ Effect on Uterine Blood Flow and Preeclampsia |
| NCT04918173 | PHASE3 | RECRUITING | Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery |
| NCT01384903 | PHASE3 | COMPLETED | An Open-label Study of KW-3357 |
| NCT01530737 | PHASE3 | COMPLETED | Antithrombin Enhancement May Improve Anticoagulation Efficiency in Infants Undergoing Cardiopulmonary Bypass for Cardiac Surgery |
| NCT03208270 | PHASE2/PHASE3 | COMPLETED | Antithrombin Supplementation in ECMO |
| NCT00823082 | PHASE2 | COMPLETED | Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass |
| NCT02037555 | PHASE2 | COMPLETED | Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass |
| NCT04745442 | PHASE2 | COMPLETED | Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19 |
| NCT04899232 | PHASE2 | TERMINATED | Antithrombin III in Infectious Disease Caused by COVID-19 |
| NCT01698567 | PHASE1 | TERMINATED | Antithrombin III in Infants With Cardiopulmonary Bypass (CPB) |
| NCT02631174 | PHASE1 | COMPLETED | Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support |
| NCT04055389 | PHASE1 | WITHDRAWN | Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis |
| NCT04219579 | Not specified | COMPLETED | Antithrombin III Concentrate After Liver Transplantation |
| NCT04651400 | Not specified | COMPLETED | Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection |
| NCT04879550 | Not specified | COMPLETED | Prospective Investigation of Antithrombin III Deficiency in Adult Patients With ECMO |
| NCT04912193 | Not specified | COMPLETED | Antithrombin III and Post-liver Transplantation Acute Kidney Injury |
| NCT07036809 | Not specified | COMPLETED | Assessment of Antithrombin III, Protein C, Protein S and D-dimer in Acute Leukemia |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).